TNF and inflammatory bowel disease: The PROSIT-BIO cohort study of 547 patients with IBD firstly suggested that 73.7% of anti-TNF naïve patients with CT-P13 treatment could achieve clinical response at week 24, which was comparable with infliximab therapy (Fiorino et al., 2017).